This new initiative will focus on accessing large clinical cohorts for validating its diagnostic products through the company’s collaborative network. Lipomics will use its analytical and bioinformatic technology to validate the clinical utility of its biomarkers associated with various aspects of fatty liver disease.
Lipomics is developing blood-based diagnostics for the early detection of non-alcoholic fatty liver disease (NAFLD), the ability to distinguish between NAFLD and non-alcoholic steatohepatitis (NASH), and other diagnostics for liver health. Lipomics’s proprietary lipid biomarkers proved effective in identifying patients with varying degrees of metabolic liver disorders in recent clinical trials.
Steve Watkins, CEO of Lipomics, said: “Our diagnostics provide non-invasive blood-based tests that will empower doctors to detect liver disorders in their earliest stages and support management of patient care where liver disease is present.”